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Abstract 
Background: The objective of the present analysis is to describe the outcomes of 
high-intensity non-invasive positive pressure ventilation (NPPV) aimed at maximally de-
creasing PaCO2 as an alternative to conventional NPPV with lower ventilator settings in 
stable hypercapnic COPD patients.   
Methods: Physiological parameters, exacerbation rates and long-term survival were as-
sessed in 73 COPD patients (mean FEV1 30±12 %predicted) who were established on 
high-intensity NPPV due to chronic hypercapnic respiratory failure between March 1997 and 
May 2006. 
Results: Controlled NPPV with breathing frequencies of 21±3 breath/min and mean inspi-
ratory/expiratory positive airway pressures of 28±5/5±1 cmH2O led to significant im-
provements in blood gases, lung function and hematocrit after two months. Only sixteen 
patients (22%) required hospitalisation due to exacerbation during the first year, with 
anaemia increasing the risk for exacerbation. Two- and five-year survival rates of all patients 
were 82% and 58%, respectively. The five year survival rate was 32% and 83% in patients 
with low (≤39%) and high (≥55%) hematocrit, respectively.   
Conclusion: High-intensity NPPV improves blood gases, lung function and hematocrit, and 
is also associated with low exacerbation rates and a favourable long-term outcome. The 
current report strongly emphasises the need for randomised controlled trials evaluating the 
role of high-intensity NPPV in stable hypercapnic COPD patients. 
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Introduction 
The effectiveness of non-invasive positive pres-
sure ventilation (NPPV) as a treatment for chronic 
hypercapnic respiratory failure (HRF) arising from 
COPD [1] remains debatable. Although long-term 
NPPV is currently used in the treatment of COPD 
patients in Europe [2], clinical outcomes such as sur-
vival, exacerbation and hospitalization rates have not 
been clearly established in favor of NPPV [3, 4, 5]. 
However, most studies have used low levels of in-
spiratory support with inspiratory positive airway 
pressures (IPAP) ranging from 12 to 18cmH2O. These 
settings have not been shown to significantly improve 
physiological parameters, particularly elevated 
PaCO2 levels [3, 4, 6]. In contrast, we have recently 
shown that NPPV is well tolerated and leads to a 
substantial improvement in blood gases and alveolar 
ventilation during spontaneous breathing when ven-
tilator settings are markedly increased [7, 8, 9, 10]. 
Since this approach uses more intense ventilator set-
tings, we have labeled this form of treatment Int. J. Med. Sci. 2009, 6 
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“high-intensity NPPV”.  
The aim of the present report is to describe the 
physiological and blood gas parameters, hospital 
admissions and mortality in patients with stable, hy-
percapnic COPD treated with high-intensity NPPV. 
 
Materials and Methods 
The study protocol was approved by the Institu-
tional Review Board for Human Studies at the Al-
bert-Ludwigs University, Freiburg, Germany, and 
was performed in accordance with the ethical stan-
dards laid down in the Declaration of Helsinki. 
High-intensity NPPV 
All patients were hospitalized to establish 
high-intensity NPPV. The assist/control mode is used 
for high-intensity NPPV, preferably in a pres-
sure-limited mode [7, 8, 9]. The major target for the 
ventilatory adjustments (mainly increasing IPAP and 
respiratory rate) is to achieve normocapnia. The initial 
settings consist of the lowest back-up rates and trigger 
threshold, with avoidance of auto triggering; these 
settings are used in conjunction with low IPAP levels, 
typically ranging between 12 and 16 cmH2O, and the 
lowest expiratory positive airway pressures (EPAP) 
levels. Subsequently, IPAP is carefully increased, step 
by step, prior to the point where it is no longer toler-
ated by the patient. Next, the respiratory rate is in-
creased beyond the spontaneous rate to establish 
controlled ventilation, while EPAP is set in order to 
avoid dynamic hyperinflation; this is usually between 
3 and 6 cmH2O, depending on individual tolerance. 
NPPV is first used during daytime under careful su-
pervision, with the main aim of establishing NPPV 
tolerance. When the patient is able to tolerate NPPV 
for more than two hours, further ventilator adjust-
ments are performed in order to optimise alveolar 
ventilation according to the results of arterial blood 
gas (ABG) analysis. Further increases in respiratory 
rate are aimed at a progressive decrease in PaCO2 
towards normocapnia, whilst maintaining an I:E ratio 
of approximately 1:2. Once daytime NPPV is toler-
ated, nocturnal NPPV is commenced. The settings are 
individually modified according to the patient’s com-
fort and nocturnal ABG. Nasal masks are initially 
used, but patients are switched to oronasal masks if 
there is increasing nocturnal PaCO2, indicative of 
leakage. Passive humidification with a heat and 
moisture exchanger is used according to patient 
comfort, with a switch to active humidication using a 
humidifier if airway dryness persists. Finally, patients 
are instructed to use the ventilator for the entire night, 
as well as during any naps taken during the daytime. 
Patients and data collection 
All patients presenting with stable hypercapnic 
COPD, as diagnosed according to international 
guidelines [11], and who received high-intensity 
NPPV between March 1997 and May 2006 at the De-
partment of Pneumology, University Hospital 
Freiburg, Germany, were registered in a hospital da-
tabase and included for analysis. Patients were ex-
cluded if they were established on NPPV during acute 
HRF (including one of the following symptoms: 
breathing frequency >30 per minute, pH <7.35), or 
received any form of invasive ventilation in the past. 
Furthermore, patients with obesity (BMI>35kg/m2) 
were excluded. 
The following data were analysed: patients’ 
characteristics, ventilator settings, blood gases at day-
time under rest, lung function testing, mouth occlu-
sion pressures, hematocrit (three groups: ≤39, 40 to 54 
and  ≥55%), haemoglobin levels, and long-term sur-
vival. In addition, hospitalisation for routine check of 
NPPV, for management of problems related to NPPV 
such as mask problems and for severe exacerbation 
[12] during the first year of NPPV was assessed  
Statistical Analysis 
Statistical analysis was performed using 
Sigma-Stat® (Version 3.1, Systat Software, Inc., Point 
Richmond, California, USA). Mean values ± standard 
deviation were given after testing for normal distri-
bution (Kolmogorov-Smirnov test). For non-normally 
distributed data, the median and interquartile ranges 
are given. Follow-up measurements were performed 
using the paired t- test for normally distributed data 
and the Wilcoxon signed rank test for non-normally 
distributed data. Five-year survival rates were as-
sessed by Kaplan-Meier actuarial curve analysis. Sta-
tistical significance was assumed with a p-value <0.05. 
 
Results 
Twenty women and 53 men, for whom COPD 
was the leading cause of chronic HRF, and who were 
established on high-intensity NPPV, were identified 
from the database. Mean age was 64.2±9.6 years and 
mean body mass index (BMI) was 27.6±6.7 kg/m2. 
Mean cumulative smoking history was 41.9±28.5 
pack-years. Pressure-limited NPPV was applied in 69 
patients (Table 1), whereas four patients were estab-
lished on volume-limited NPPV, due to better toler-
ance with a mean tidal volume of 683±197 ml and a 
mean breathing frequency of 21.3±3.8/min. Changes 
in physiological parameters after two months of 
NPPV are given in Table 2. After one year of NPPV, 
PaCO2 decreased from 51.7±6.6 to 44.9±12.7 (95%CI Int. J. Med. Sci. 2009, 6 
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-11.6/-1.9; p=0.008) while PaO2 increased from 
53.1±8.9 to 65.1±11.7 (95%CI 7.6/15.6; p<0.001). In 13 
patients (18%), hematocrit was ≤39%; in 53 patients 
(73%), hematocrit ranged from 40 to 54%; and in seven 
patients (9%), hematocrit was ≥55%. Although hema-
tocrit decreased significantly in the total group after 
two months of NPPV (Table 2), hematocrit increased 
from 36.2 (interquartile range 35.8/38.9) to 37.5 (in-
terquartile range 36.0/39.5)% (p=0.016) in patients 
with an initial hematocrit ≤39%, but decreased from 
55.8±0.9 to 48.2±5.7% (95%CI -13.6/-1.6; p=0.022) in 
patients with an initial hematocrit ≥55%, and from 46 
(interquartile range 43.1/48.9) to 44.2 (interquartile 
range 42.1/46.3)% (p=0.008) in patients with an initial 
hematocrit ranging from 40 to 54%.   
 
Table 1. Ventilator settings for 69 patients receiving 
pressure-limited NPPV 
 
 
  Mean ± SD  Min  Max 
IPAP (cmH2O)  28.0 ± 5.4  17  42 
EPAP (cmH2O)  4.6 ± 1.3  2  9 
bf (/min)  21.0 ± 2.8  10  26 
Supplemental oxygen 
(l/min) 
1.6 ± 1.5  0  6 
IPAP = inspiratory positive airway pressure, EPAP = expiratory 
airway pressure, bf = breathing frequency; SD = standard deviation. 
 
 
Table 2. Blood gas levels, lung function parameters, mouth occlusion pressures, hemoglobin and hematocrit prior to NPPV 
and 2 months after establishment of NPPV. 
Variables    prior to NPPV  After 2 months of NPPV  95 % CI for the difference  p-value 
pH   7.40 ± 0.04  7.40 ± 0.03  -0.01 / 0.02  0.598 
PaCO2 (mmHg)    51.2 ± 6.5  46.8 ± 5.8  -6.2 / -2.0  <0.001 
PaO2 (mmHg)   53.0 ± 8.1  58.0 ± 8.3  2.1 / 7.9  0.001 
HCO3- (mmol/L)   31.3 ± 5.7  28.7 ± 5.4  -4.0 / -1.2  <0.001 
TLC (%pred.)   109.2 ± 22  109.3 ± 21.6  n.f.  0.419 
FVC (%pred.)   49.3 ± 13.3  54.6 ± 13.7  2.2 / 8.2  <0.001 
FEV1 (%pred.)   30.1 ± 12.2  34.6 ± 13.6  2.4 / 6.6  <0.001 
FEV1/FVC (%)   43.6 ± 10.1  45.6 ± 10.7  n.f.  0.68 
P0.1 (kPa)  0.60 ± 0.57  0.46 ± 0.26  n.f.  0.056 
PImax (kPa)   4.7 ± 2.3  5.6 ± 2.5  n.f.  0.501 
Hb (g/dl)   14.6 ± 2.0  14.2 ± 1.7  -0.9 / -0.1  0.093 
Hkt (%)   45.1 ± 6,5  43.7 ± 5.9  n.f.  0.005 
n.f. = normality test failed. PaCO2 = arterial partial pressure of carbon dioxide, PaO2 = arterial partial pressure of oxygen, HCO3- = bicar-
bonate, TLC = total lung capacity, FVC = forced vital capacity, FEV1 = forced expiratory volume in one second, P0.1 = mouth occlusion 
pressure 0.1 seconds after the onset of inspiration during normal breathing, PImaxpeak = peak maximal inspiratory mouth pressure according 
to previous findings [21], Hb = hemoglobin, HKT = hematocrit. 
 
 
Routine checks were performed 1.9±0.8 times in 
the first year (9.1±6.3 days in hospital). Additionally, 
11 patients (15%) were admitted to hospital on 1.3±0.9 
occasions for the management of problems associated 
with NPPV (8.0±5.8 days in hospital). Sixteen patients 
(22%) required hospitalisation 1.3±0.6 times (19.3±10.9 
days) during the first year due to exacerbation (one of 
these patients died in hospital and two patients re-
quired ICU admission with one requiring intubation). 
Hospitalisation for an acute exacerbation was re-
quired in five patients (46%) with a hematocrit <39%, 
while no patient with a hematocrit >55% was hospi-
talised in the first year following commencement of 
NPPV. In all patients, two- and five-year survival 
rates were 82±5% and 58±8%, respectively. The me-
dian survival was 78 months. In those patients with a 
hematocrit <39%, five year survival was 32%, com-
pared to 83% in those with a hematocrit >55%. 
Discussion 
Stable hypercapnic COPD-patients analysed in 
the present study performed high-intensity NPPV 
over several years and thereby demonstrated an im-
provement in blood gases; this is in agreement with 
previous findings [7, 8, 9]. The present study extends 
the existing experience with high-intensity NPPV in 
COPD by particularly addressing important clinical 
aspects of its impact on exacerbation and hospitalisa-
tion. As shown in the present study hospitalisa-
tion-rates are acceptable once high-intensity NPPV 
has been successfully established. Importantly, only 
22% of patients required hospitalisation due to exac-Int. J. Med. Sci. 2009, 6 
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erbation during the first year, with most patients be-
ing successfully treated on the general ward. This 
challenges previous findings, where >50% of patients 
required hospitalisation during a one year follow-up, 
although the disease in these patients was less ad-
vanced [13].  
Moreover, the five year survival rate was 58%, 
suggesting that high-intensity NPPV has survival 
benefits compared to historical data [14, 15, 16]. 
Anaemia was associated with higher rates of exacer-
bation and reduced long-term survival, confirming 
previous findings [17]. The present study gives un-
controlled evidence that hematocrit has an important 
impact on long-term outcome in COPD-patients re-
ceiving home mechanical ventilation. However, he-
matocrit also normalised within two months of 
high-intensity NPPV. In addition, there was an im-
provement in lung function parameters, which is in 
line with previous studies [8, 18]. The explanation for 
this observation remains unclear. However, hyper-
capnia, with consequent dilation of precapillary 
sphincters, is believed to be the predominant factor 
c a u s i n g  e d e m a  i n  p a t i e n t s  w i t h  s e v e r e  C O P D  [ 1 9 ] .  
Since this edema could also affect the bronchial tree, 
improvements of lung function might be attributed to 
the decrease in PaCO2, thus reversing bronchial 
edema. However, this remains speculative and needs 
to be investigated in future studies. Finally, overall 
health-related quality of life has most recently been 
shown to increase substantially following the estab-
lishment of high-intensity NPPV, and these im-
provements were reported to be similar when com-
pared to patients with neuromuscular and thoracic 
restrictive diseases [20].  
Several questions, howev e r ,  n e e d  t o  b e  a d -
dressed: Firstly, selection criteria must be established. 
Unfortunately, this was not performed in the present 
study due to its retrospective nature. Secondly, 
drop-outs and compliance rates have not been quan-
tified. This seems to be important as selection of those 
patients who tolerate high-intensity NPPV would 
result in better outcomes. Therefore, prospective trials 
also assessing the number of patients not tolerating 
high-intensity NPPV are required. Thirdly, 
high-intensity NPPV, as described in the present 
study, seems to be the extreme opposite to the con-
ventional technique of using considerably lower ven-
tilator settings. Therefore, controlled studies are 
needed to compare these techniques in the future.  
In conclusion, application of high-intensity 
NPPV, described both here and in the literature, im-
proves alveolar ventilation and consequently blood 
gases during spontaneous breathing, as well as lung 
function and hematocrit in stable hypercapnic COPD 
patients. In addition, with regard to the present study, 
there is uncontrolled evidence of high-intensity NPPV 
being capable of reducing exacerbation rates and im-
proving long-term survival. Therefore, the current 
report strongly emphasises the need for randomised 
controlled trials evaluating the role of high-intensity 
NPPV in COPD patients with chronic HRF.  
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